Go to the list of all blogs
Jimmy Landsman's Avatar
published in Blogs
Sep 23, 2026
METU: 2X Leveraged Exposure to Meta Platforms (META) Delivers +27% in 30 Days

METU: 2X Leveraged Exposure to Meta Platforms (META) Delivers +27% in 30 Days

Key Takeaways

  • METU is a leveraged single-stock exchange-traded fund (ETF) that seeks 200% of the daily return of Meta Platforms (META), amplifying both gains and losses.
  • Over the trailing 30 days, METU rose roughly 27%, as Meta shares climbed about 14%.
  • Across the trailing three months, METU advanced roughly 29%, rebounding from a sharp post-earnings selloff in late July.
  • The recent rally followed the launch of Meta's Muse AI agent, an $18 billion litigation settlement, and a round of analyst upgrades.
  • Because the fund resets daily, its multi-day returns can diverge materially from 2X the underlying due to compounding and volatility.

Understanding METU's Structure and Portfolio Exposure

Direxion Daily META Bull 2X Shares is a leveraged single-stock ETF launched in June 2024. The fund seeks daily investment results, before fees and expenses, equal to 200% of the daily performance of Meta Platforms (META), and normally invests at least 80% of its net assets in Meta securities plus financial instruments such as swap agreements and options. It is non-diversified and concentrates its exposure in a single company, with roughly 100% of its long equity exposure in the Communication Services sector. The largest holding is Meta Platforms itself at approximately 18% of net assets, with the remainder largely held in cash and short-term government and Treasury instruments serving as collateral for the derivatives that create the leverage. The net expense ratio is 1.02%, and net assets have been reported in a range of roughly $360 million to $485 million. This concentrated, levered structure explains the fund's outsized swings: when Meta moves, METU tends to move roughly twice as much on a single-day basis. I also checked this using Tickeron’s AI Screener to see how the fund compares to others in the leveraged ETF space.

Recent Performance: 30 Days and the Quarter

Over the trailing 30 days, METU climbed about 26.7% — from roughly $21.18 to $26.84 — a move of approximately 27%. The path was not linear: the fund spent much of August in a choppy, range-bound pattern before a sharp, trend-driven advance in early-to-mid September. Over the trailing three months, the fund rose about 28.8%, or roughly 29%, from approximately $20.84 in mid-June. Notably, that quarterly gain is less than twice Meta's roughly 18% advance over the same window, reflecting the compounding and volatility effects inherent to a daily-reset leveraged product after the late-July drawdown.

Catalysts Behind the 30-Day Rally

The recent 30-day surge was almost entirely a function of Meta's own rally, which added about 13.6% over the window. Several catalysts converged in September. Meta introduced Muse, a consumer AI agent, which analysts framed as a meaningful step toward monetizing its billions of users; the stock rose about 6.5% in a single session following the launch. The company also settled long-running social-media litigation for $18 billion, removing a significant legal overhang that some had feared could be far larger. JPMorgan subsequently upgraded Meta to Overweight and raised its price target to $820, while Evercore ISI and Mizuho issued constructive commentary. This combination of product momentum, reduced legal risk, and improving analyst sentiment re-rated Meta's shares, and the 2X leverage translated that move into a roughly 27% gain for METU.

Quarterly Trends and Earnings Impact

The broader three-month trend was shaped by a first-half decline followed by recovery. In late July, Meta reported second-quarter results that beat on revenue — revenue rose 28% to about $60.8 billion — but missed on profit, with diluted earnings per share (EPS) of $6.18 versus expectations near $7.22. Free cash flow (FCF) collapsed 91% year over year to roughly $784 million as capital expenditures reached about $31 billion in the quarter, and the company guided full-year capex to $130 billion–$145 billion. Meta shares fell about 8% the next session, and METU dropped roughly 16%. The fund then recovered as AI optimism and the September catalysts took hold. From what I see, a single large holding and daily leverage make METU's quarterly performance highly sensitive to Meta's earnings cycles, sentiment, and AI-spending narrative.

Key Factors to Monitor Going Forward

Investors should monitor several structural factors. First, Meta's AI investment cycle: 2026 capital expenditure guidance of $130 billion–$145 billion is pressuring free cash flow, and the pace of AI monetization will determine how quickly profitability recovers. Second, adoption and monetization of Muse and other consumer AI products, which remain early-stage. Third, the core digital-advertising business, which continues to be the primary driver of revenue. Fourth, the macroeconomic environment — interest rates and inflation affect valuations for mega-cap growth names and can amplify volatility through METU's leverage. Finally, regulatory and legal risks around privacy, competition, and platform safety, as well as daily-reset mechanics, remain key considerations. Because METU seeks 2X daily exposure, holding periods longer than one day can produce returns that differ from 2X Meta's return, especially in volatile markets. I’m watching this closely as the next earnings cycle approaches.

Using AI Tools for Deeper Analysis

In my research on leveraged products like METU, Tickeron’s AI Screener has proven useful for quickly scanning technical indicators, volatility metrics, and performance patterns across similar funds. It helps surface candidates that align with specific criteria without manual effort, letting me focus on the details that matter most for position sizing and risk management. The AI Screener automates much of the initial comparison work, which is particularly handy when evaluating how daily-reset leverage interacts with underlying moves in names like Meta Platforms.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: METU

Contributor

My name is Jimmy, and I’m a financial analyst focused on identifying compelling opportunities across the ETF market. Each day, I analyze hundreds of ETFs to uncover potential trading and investment opportunities using a broad range of market factors. For short-term trading, I rely heavily on technical analysis, including price channels, momentum indicators, support and resistance levels, trend patterns, and other market signals. At the same time, I dedicate significant attention to evaluating ETFs from a long-term investment perspective. My objective is to build a well-balanced ETF portfolio that combines core investment holdings with more tactical and speculative positions. The goal is to create a portfolio that can participate effectively in market rallies while also remaining resilient during periods of volatility and market corrections.


METU's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for METU turned positive on August 26, 2026. Looking at past instances where METU's MACD turned positive, the stock continued to rise in 17 of 18 cases over the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on August 31, 2026. You may want to consider a long position or call options on METU as a result. In 33 of 37 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 89%.

METU moved above its 50-day moving average on September 03, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for METU crossed bullishly above the 50-day moving average on September 11, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 5 of 6 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 83%.

Following a +3.43% 3-day Advance, the price is estimated to grow further. Considering data from situations where METU advanced for three days, in 135 of 147 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.

The Aroon Indicator entered an Uptrend today. In 58 of 63 cases where METU Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.

Bearish Trend Analysis

The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 12 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

METU broke above its upper Bollinger Band on September 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Notable companies

The most notable companies in this group are Meta Platforms (NASDAQ:META).

Industry description

The investment seeks daily investment results, before fees and expenses, of 200% of the daily performance of META. The fund, under normal circumstances, invests at least 80% of its net assets (plus any borrowings for investment purposes) in the securities of META and financial instruments, such as swap agreements and options, that, in combination, provide 2X daily leveraged exposure to META, consistent with the fund’s investment objective. The fund is non-diversified.

High and low price notable news

The average weekly price growth across all stocks in the Direxion Daily META Bull 2X ETF (METU) ETF was 10%. For the same ETF, the average monthly price growth was 34%, and the average quarterly price growth was 35%. META experienced the highest price growth at 11%, while META experienced the biggest fall at 11%.
View a ticker or compare two or three
METU
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Category Trading

Category
Trading--Leveraged Equity
Address
Direxion Shares ETF Trust33 Whitehall Street,10th FloorNew York
Phone
866-476-7523
Web
http://www.direxioninvestments.com/
Interact to see
Advertisement
The Fed kept rates at 3.5–3.75% and signaled a “higher for longer” stance, with no urgency to cut and a willingness to tighten again if inflation stalls. This backdrop tends to favor quality growth, financials, energy, industrials, and health care, while pressuring long‑duration, leveraged sectors like speculative tech, small caps, utilities, and REITs.
PICS shares fell over 20% today, reversing much of their post‑IPO bounce and dropping well below the US$19 IPO price after initially trading in the mid‑US$15–16 range. The selloff followed PicPay’s Q4 and full‑year 2025 results, which showed strong revenue growth but highlighted thin margins, intense competition and ongoing execution risk in credit underwriting and payments.
RCAT shares fell over 16% today, dropping from recent levels near US$17 toward the mid‑US$14–15 range, after trading as high as US$18.78 in the past year and more than tripling from a 52‑week low of US$4.60.
HYMC shares fell over 13% today, sliding from the mid‑US$30s toward roughly US$31, after trading between US$2.30 and US$58.73 over the past 12 months and closing near US$39 just a few sessions ago.
USAS fell over 10% today, trading around US$5.83 by early afternoon from a previous close of US$6.55 — a one‑day decline of roughly 11% — as more than 5.9 million shares changed hands. The stock had surged earlier in 2026, with some data showing a move from about US$1.11 in March 2025 to over US$7.30 in mid‑March 2026 — a gain of more than 500% — leaving it vulnerable to profit‑taking.
CENX fell about 8.9% today, dropping US$4.94 to US$50.40 by midday, after closing at US$55.34 yesterday; shares now sit roughly 15% below their 52‑week high of US$59.12 but remain far above the 12‑month low of US$13.05. Q4 2025 results showed net sales of US$633.7 million and adjusted net income of US$128.2 million (US$1.25 per share), with adjusted EBITDA of US$170.6 million — a big sequential improvement — but GAAP net income was just US$1.8 million (US$0.02 per share), underscoring earnings volatility.
CNL shares fell over 8% today, trading down from around C$22.90 toward the low‑C$21s, after recently setting a new 1‑year high at C$28.99 on March 2 and gaining more than 70% over the past 12 months.
SMCI shares are plunging approximately 26% in Friday premarket trading, extending sharp after-hours losses from Thursday's session close of $30.79. The primary catalyst is a federal indictment unsealed March 19, 2026, charging three individuals associated with Super Micro — including a company co-founder — with conspiring to illegally export billions of dollars in AI server technology to China.
PL shares are surging approximately 19% in premarket trading on March 20, 2026, building on an 8.67% gain during the regular session on March 19. The primary catalyst is a blowout Q4 fiscal year 2026 earnings report released after the close on March 19, with quarterly revenue of $86.8 million — an 11.55% beat against consensus expectations of $77.81 million.
Unusual Machines (UMAC) is trading down approximately -8.60% in premarket on March 20, 2026, extending losses from the prior session. The primary catalyst is a proposed public stock offering announced after the market close on March 19, 2026, raising dilution concerns among investors.
FDX surged approximately 7% in premarket trading on March 20, 2026, moving from the prior session close of $356.11 to around $381. The primary catalyst is a blowout fiscal Q3 2026 earnings report, with adjusted EPS of $5.25 — beating Wall Street's consensus estimate of $4.13 by more than 27%.
Kingsoft Cloud Holdings Limited (KC) shares plunged about 9% in the most recent session, extending a sharp pullback after a recent rally. The selloff reflects mounting concerns around profitability, with the company still loss-making and showing weak multi-year revenue growth.
BAK shares fell roughly 11% in the latest trading session, marking a sharp single-day drop for the Brazilian petrochemical producer The decline comes amid persistent concerns about high leverage, a weaker credit profile, and soft petrochemical margins in a challenging macro environment for chemicals​
INSM shares are surging approximately +10% in premarket trading on Monday, March 23, 2026, from a prior close of $136.00, placing the premarket price near $149.60. The primary catalyst is the release of positive topline results from the Phase 3 ENCORE trial of ARIKAYCE® in patients with newly diagnosed or recurrent MAC (Mycobacterium avium complex) lung disease — a readout Insmed had flagged as expected in "March or April 2026".
CF shares are trading approximately -6% lower in Monday's premarket session, dropping from a Friday close of $124.90 to approximately $117.41. Primary catalyst: President Trump announced a five-day pause on strikes against Iranian energy infrastructure following "very good" diplomatic signals, triggering a sharp unwind of the geopolitical risk premium embedded in fertilizer stocks.
APGE shares surged approximately 16% in premarket trading on March 23, 2026, after the company announced positive 52-week data from Part A of its Phase 2 APEX clinical trial. The primary catalyst is a highly anticipated clinical readout showing that zumilokibart (APG777) delivered durable and deepening responses in patients with moderate-to-severe atopic dermatitis at both every 3-month and 6-month dosing intervals.
Shares of VALN are plummeting approximately 35% in Monday's session, from a Friday close of $10.66 to roughly $6.93, in heavy volume trading. The primary catalyst is the release of Phase 3 VALOR trial topline results for Valneva's Lyme disease vaccine candidate, co-developed with PFE (Pfizer) — results that showed strong clinical efficacy but failed to meet the pre-determined statistical criterion for the primary endpoint.
AXTI is surging approximately +11.00% in Monday's session, trading near $60.21, up from a prior closing price of $54.24. The move extends the stock's post-earnings rally that began last Thursday when shares jumped more than 19% following AXT's Q4 2025 results.
Tower Semiconductor (TSEM) shares are surging approximately +10% intraday on Monday, March 23, trading around $180, up from the previous close of $163.63 on March 20, 2026. The primary catalyst is the opening day of APEC 2026 in San Antonio, Texas, where Tower Semiconductor is presenting its newly unveiled Gen3 BCD power management platform designed to address escalating AI data center power demands.
CD is indicated down about 17% in premarket trading after the latest completed session, pointing to a sharp negative market reaction heading into the open. The stock’s weakness comes against a backdrop of lingering uncertainty following its privatization and delisting process from Nasdaq, which has left limited liquidity and a thinner news flow around the name.